Fructus Psoraleae-Induced Severe Liver Injury and Treatment With Two Artificial Liver Support Systems: A Case Series Study.
Chemical and Drug Induced Liver Injury
/ blood
China
/ epidemiology
Combined Modality Therapy
/ methods
Drugs, Chinese Herbal
/ administration & dosage
Fabaceae
/ adverse effects
Female
Hemofiltration
/ methods
Humans
Liver Function Tests
/ methods
Liver, Artificial
Male
Middle Aged
Monitoring, Physiologic
/ methods
Plant Extracts
/ administration & dosage
Plasma Exchange
/ methods
Plasmapheresis
/ methods
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Artificial liver support system
Drug-induced liver injury
Fructus Psoraleae
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
revised:
17
09
2019
received:
26
05
2019
accepted:
20
09
2019
pubmed:
3
10
2019
medline:
15
12
2021
entrez:
3
10
2019
Statut:
ppublish
Résumé
To describe the clinical features and outcomes of patients with suspected Fructus Psoraleae (FP)-induced severe liver injury who underwent treatment with two artificial liver support systems (ALSSs). The cases of 12 patients with severe liver injury by FP were enrolled. We evaluated the tolerability of, and changes in biochemical parameters after treatment with plasma exchange combined with hemofiltration and double plasma molecular absorption system, and 6-month follow-up information were collected. The median age of the 12 patients was 60 years and nine (75%) patients were females. All patients had jaundice as the initial symptom. Two ALSS types were used to treat the patients. The group that underwent plasma exchange combined with hemofiltration showed remarkable improvements in ALT, AST, total bilirubin (TB), GGT and international normalized ratio levels (AST, TB, international normalized ratio, P < 0.01; ALT, GGT, P < 0.05), and the levels of AST, ALP, TB, and total bile acid decreased significantly in the double plasma molecular absorption system group after treatment (TB, P < 0.01; AST, ALP, total bile acid P < 0.05). During 6 months of follow-up, two patients died, two became chronic, and eight recovered to normal. FP can cause clinically severe liver injury, characterized by gastrointestinal symptoms and jaundice, which can lead to death or become chronic. Both ALSSs were safe and well tolerated in drug-induced liver injury patients. After ALSS treatment, the levels of biochemical indicators of liver function improved significantly, indicating that ALSS might be beneficial for patients with severe drug-induced liver injury.
Identifiants
pubmed: 31577858
doi: 10.1111/1744-9987.13438
doi:
Substances chimiques
Cullen corylifolium extract
0
Drugs, Chinese Herbal
0
Plant Extracts
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
324-332Subventions
Organisme : Key Research and Development Project of the Department of Science and Technology of Zhejiang Province
ID : 2017C03051
Organisme : Zhejiang Provincial Natural Science Foundation of China
ID : LY17H030005
Informations de copyright
© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Chalasani N, Bonkovsky HL, Fontana R et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015;148:1340-52.e7.
Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014;4:177.
Li YG, Hou J, Li SY et al. Fructus Psoraleae contains natural compounds with potent inhibitory effects towards human carboxylesterase 2. Fitoterapia 2015;101:99-106.
Yang J, Yang J, Du J et al. General survey of Fructus Psoraleae from the different origins and chemical identification of the roasted from raw Fructus Psoraleae. J Food Drug Anal 2018;26:807-14.
Cheung WI, Tse ML, Ngan T et al. Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine. Clin Toxicol 2009;47:683-5.
Zhao ZJ, Gong Z, Shi SZ, Yang JL, Ma NN, Wang Q. [Toxicokinetics of bakuchiol, hepatic and renal toxicity in rats after single oral administration of Psoraleae Fructus and combination with Glycyrrhizae Radix et Rhizoma]. Zhongguo Zhong Yao Za Zhi 2015;40:2221-6.
Tian WY, Lan S, Zhang L et al. Safety evaluation and risk control measures of Psoralea corylifolia. Zhongguo Zhong Yao Za Zhi 2017;42:4059-66.
Li ZJ, Abulizi A, Zhao GL et al. Bakuchiol contributes to the hepatotoxicity of Psoralea corylifolia in rats. Phytother Res 2017;31:1265-72.
Nam SW, Baek JT, Lee DS, Kang SB, Ahn BM, Chung KWA. Case of acute cholestatic hepatitis associated with the seeds of Psoralea corylifolia (Boh-Gol-Zhee). Clin Toxicol 2005;43:589-91.
Larsen FS, Schmidt LE, Bernsmeier C et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol 2016;64:69-78.
Donati G, Piscaglia F, Coli L et al. Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis. Aliment Pharmacol Ther 2007;26:717-26.
Kribben A, Gerken G, Haag S et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012;142:782-9 e3.
Banares R, Nevens F, Larsen FS et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013;57:1153-62.
Wan Y-M, Li Y-H, Xu Z-Y et al. Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entercavir: a prospective study. J Clin Apher 2017;32:453-61.
Flamm SL, Yang YX, Singh S, Falck-Ytter YT. American Gastroenterological Association Institute guidelines for the diagnosis and management of acute liver failure. Gastroenterology 2017;152:644-7.
Chalasani NP, Hayashi PH, Bonkovsky HL et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109:950-66; quiz 67.
Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30.
Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-6.
Fontana RJ, Seeff LB, Andrade RJ et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52:730-42.
Wendon J, Cordoba J, Dhawan A et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017;66:1047-81.
Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. [Guideline for diagnosis and treatment of liver failure]. Zhonghua Gan Zang Bing Za Zhi 2019;27:18-26.
Vuppalanchi R, Navarro V, Vega M et al. Herbal dietary supplement associated hepatotoxicity: an upcoming workshop and need for research. Gastroenterology 2015;148:480-2.
Fontana RJ, Hayashi PH, Barnhart H et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol 2015;110:1450-9.
de Boer YS, Kosinski AS, Urban TJ et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol 2017;15:103-12 e2.
Bonkovsky HL, Kleiner DE, Gu J et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology 2017;65:1267-77.
Chopra B, Dhingra AK, Dhar KL. Psoralea corylifolia L. (Buguchi)-folklore to modern evidence: review. Fitoterapia 2013;90:44-56.
Wang XX, Lv X, Li SY et al. Identification and characterization of naturally occurring inhibitors against UDP-glucuronosyltransferase 1A1 in Fructus Psoraleae (Bu-gu-zhi). Toxicol Appl Pharmacol 2015;289:70-8.
Wang J, Jiang Z, Ji J et al. Evaluation of hepatotoxicity and cholestasis in rats treated with EtOH extract of Fructus Psoraleae. J Ethnopharmacol 2012;144:73-81.
Li LJ, Zhang YM, Liu XL et al. Artificial liver support system in China: a review over the last 30 years. Ther Apher Dial 2006;10:160-7.
Nevens F, Laleman W. Artificial liver support devices as treatment option for liver failure. Best Pract Res Clin Gastroenterol 2012;26:17-26.